Czech and Slovak Ophthalmology 479 Original article Preservative Substances – the Daily Dose of Benzalkonium Chloride in Glaucoma Treatment from the Patient’s Point of View Výborný Petr Sičáková Silvia Veselá Flórová Zuzana 15 5 2014 3 3

The author calculated the daily dose of Benzalkonium Chloride (BAC) in eye drops used in glaucoma treatment from the patient’s point of view, which means the real amount of BAC applied in the conjunctival sac. The information about BAC concentration in 1 milliliter (mL) do not offer sufficient picture about real circumstances, because the size of the drop, especially after the introducing of the use of generic products in clinical practice in specific anti-glaucomatic drugs, differs significantly. The daily dose of BAC may have substantial significance in the patient’s treatment tolerance. The overview of BAC daily dose in single therapeutic groups and drugs follows: betablockers: Timo-COMOD 0, Arutimol 2.6, Vistagan 2.8, Timolol-POS 3.0, Arteoptic 3.7, Betoptic S 4.8, TimoptolMSD 6.3, Betoptic 10.0; alpha-mimetics: Alphagan 3.5, Luxfen 3.5, Aruclonin 7.1; derivates of prostaglandine, prostamides: Taflotan 0, Monopost 0, Lumigan 1.4, Unilat 3.1, Travatan 3.9, Latanoprost Apotex 4.3, Rescula 5.8, Latanoprost POS 5.9, Xalatan 6.0, Latanoprost Ratiopharm 6.0, Latanoprost Actavis 6.0, Latanoprost Arrow 6.0, Arulatan 5.4, Latalux 6.0, Glaucotens 6.0, Xaloptic 6.0, Solusin 6.1; carboanhydrase inhibitors: Batidor 3.8, Azopt 4.8, Trusopt 5.4,Oftidor 8.1; fixed combinations: Ganfort 1.4, Dorzolamid/timolol TEVA 2.8, Combigan 3.2, Duotrav 4.3, Cosopt 5.6, Xalacom 6.0, Glaucotima 6.0, Latanoprost/timolol Apotex 6.3, Azarga 6.4, Dorzogen Combi 6.5, and Dozotima 8.8 μl.

 glaucoma antiglaucomatic treatment preservatives Benzalconium Chloride BAC daily dose of BAC References Ammar, D.A., Noecker, R.J., Kaho- ok, M.Y.: Effects of benzalkonium chlo- ride-preserved, and sofZia-preserved topical glaucoma medications on hu- man ocular epithelial cells. Advances in Therapy, 27; 2010: 837–845. Anvar, Z., Wellik, S.R., Galor, A.: Glaucoma therapy and ocular surface disease. Curr Opin Ophthalmol, 24; 2013: 136–143. Baudoin, C.: Side effects of antiglau- comatous drugs on the ocular surface. Curr Opin Ophthalmol, 7; 1996: 80–86. Baudoin, C., Abbé, A., Liang, H., et al.: Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res, 29; 2010: 312–334. Brasnu, E., Brignole-Baudoin, F., Riancho, L. et al.: In vitro effects of preservative-free tafluprost and pre- served latanoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res, 27; 2008: 303–312. Cantor, L.B., Liu, C.C., Batoosingh, A.L., et al.: Safety and tolerability of brimonidine purite 0,1% and brimonidi- ne 0,15%: a metaanalysis of the pha- se 3 studies. Curr Med Res Opin, 25; 2009: 1615–1620. Hopes M, Broadway D.: Preservative-free treatment in glaucoma is a sensible and realistic aim for the futu- re. European Ophthalmic Review, 4, 2010: 23–28. Kahook,M.Y., Noecker, R.: Quanti- tative analysis of conjunctival goblet cells after chronic application of topical drugs. Adv Ther, 25; 2008: 743–751. Karhanová, M., Mlčák, P., Fryšák, Z., et al.: Účinnost a snášenlivost taflupro- stu 0,0015% bez konzervačních látek v léčbě glaukomu a oční hypertenze. Čes a Slov Oftal, 68; 2012: 150–155. Lewis, R.A., Katz, G., Weiss, M.J., et al.: Travoprost 0,004% with and without benzalkonium chloride: a com- parisosn of safety and efficacy. J Glau- coma, 16, 2007: 98–103. Noecker, R., Miller, K.V.: Benzalkonium chloride in glaucoma medications. Ocul Surf, 9; 2011: 159–162. Pisella, P. J., Pouliquen, P., Baudoin, C.: Prevalence of ocular symptoms and signs with preserved and pre- servative free glaucoma medication. Br J Ophthalmol, 86; 2002: 418–423. Ryan, G. Jr., Fain, J.M., Lovelace, C., et al.: Effectiveness of ophthalmic so- lution preservatives: a comparison of latanoprost with 0,02% benzalkonium chloride and travoprost with the sofZia preservative system. BMC Ophthalmo- logy, 21, 2011, 11:8, doi 10.1186/1471- 2415-11-8, dostupné na http://www. biomedcentral. com/1471-2415/11/8.10.1186/1471- Tressler, C. S., Beatty, R., Lemp, M.A.: Preservative use in topical glaucoma medications. Ocul Surf, 9; 2011: 140–158. Valente, C., Iester, M.: Impact of glaucoma medication on ocular tissue. Expert Rev Ophthalmol, 5; 2010: 405–412. Výborný, P., Sejčková, L.: Antigla- ukomatika – obsah konzervačních lá- tek a spolupráce pacienta v léčebném režimu. Čes a Slov Oftal, 62; 2006: 270–274. Výborný, P., Sičáková, S.: Denní dávka benzalkonium chloridu – významné kritérium v léčbě glaukomu. Čes a Slov Oftal, 67; 2011: 63–66. Výborný, P., Sičáková, S., Dohnalo- vá, P., et al.: Terapie glaukomu – aktuální přehled dat a informací. Čes a Slov Oftal, 69; 2013: 118–126. Yee, R.W.: The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Current Opi- nion in Ophthalmol, 18; 2007: 134–139.